ArticleCurrent oncology (Toronto, Ont.)2022
Association between Temporal Muscle Thickness and Overall Survival in Non-Small Cell Lung Cancer Patients with Brain Metastasis.
Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- Article
- Association of sarcopenia with survival and treatment response in brain metastasis of non-small cell lung cancer.Scientific reports · 2026Article
- Two-arm study of sarcopenia in geriatric patients with high-grade glial tumors: temporal muscle thickness and prognostic nutritional index.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Associations between masseter and temporal muscle measurements and sarcopenia and nutritional status in older adults.Radiologie (Heidelberg, Germany) · 2025Article
- The Influence of Muscle Morphology on Oncological Outcomes: A Review.Journal of frailty, sarcopenia and falls · 2025Review
- Melatonin protects against sarcopenia in middle-aged mice.Histology and histopathology · 2025Article
- Comprehensive Evaluation of Frailty and Sarcopenia Markers to Predict Survival in Glioblastoma Patients.Journal of cachexia, sarcopenia and muscle · 2025Article
- Age- and sex-adjusted CT-based reference values for temporal muscle thickness, cross-sectional area and radiodensity.Scientific reports · 2025Article
- The velocity of temporalis muscle wasting in cerebral metastasis is prognostic for poor survival.Frontiers in oncology · 2025Article
- Temporal Muscle Thickness and Sarcopenia Components in Healthy Adults, Validated through Allgeun Diagnostic Tool.Healthcare (Basel, Switzerland) · 2024Article
- Temporal Muscle Thickness Compared to Functional Scales as a Prognostic Parameter in Patients with Brain Metastases.Cancers · 2024Article
- Temporal muscle thickness is not a prognostic predictor in patients with high-grade glioma, an experience at two centers in China.Open medicine (Warsaw, Poland) · 2024Article
- Initial Temporal Muscle Thickness and Area: Poor Predictors of Neurological Outcome in Aneurysmal Subarachnoid Hemorrhage in a Central European Patient Cohort.Journal of clinical medicine · 2023Article
- Validation of the initial brain metastasis velocity in non-small cell lung cancer at a single cancer center.Journal of neuro-oncology · 2023Article
- Advances in the relationship between temporal muscle thickness and prognosis of patients with glioblastoma: a narrative review.Frontiers in oncology · 2023Review
- Temporal Muscle Thickness Correlates with Sarcopenia in Parkinson's Disease.Journal of Parkinson's disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temporal muscle thickness (TMT) has recently been suggested as a novel biomarker of sarcopenia in head and neck malignancies. However, few studies have evaluated TMT as a prognostic marker in patients with brain metastasis. This study investigated the association of TMT with overall survival (OS) in non-small cell lung cancer (NSCLC) patients with brain metastasis. The records of all NSCLC patients with brain metastasis between 2009 and 2018 at St. Vincent’s Hospital were reviewed retrospectively. A total of 221 patients met our eligibility criteria. In the group with TMT thicker than the median, OS was longer than the group with TMT thinner than the median (240 days versus 139 days, p = 0.014). In multivariate analysis, the thicker TMT group had longer survival (HR 0.73 CI 0.56−0.96, p = 0.024). Male (HR 1.58 CI 1.19−2.09, p = 0.002) and older age (≥65 years) (HR 2.05 CI 1.53−2.74, p < 0.001) also showed statistical significance. We also performed subgroup analysis in older patients (≥65 years). In this subgroup of 107 patients, the thicker TMT group also showed longer OS than the thinner TMT group (209 days versus 82 days, p = 0.009). Our findings suggest that TMT can be a useful biomarker for OS in NSCLC patients with brain metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.